Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:35 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Cannabidiol for Alcohol Use Disorder
NCT03904849 · Medical University of South Carolina · PHASE1/PHASE2 · withdrawn · last registry update 2024-09-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study was intended to produce pilot data for a center grant component that will no longer be conducted.” | – | Registry record, Medical University of South Carolina |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CNR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-09-11Results posted on the registry: Defined Research, Defined CBD + Placebo (NCT05233761)
- 2025-08-29Phase 3 first posted: Johns Hopkins University, Cannabidiol (CBD) + Placebo (NCT07148843)
- 2025-08-29Phase 3 first posted: Montefiore Medical Center, Dronabinol Capsules + Epidiolex 100 mg/mL Oral Solution (NCT07148206)
- 2025-08-19Results posted on the registry: Yale University, [18F]FPEB with PET (NCT05664763)
- 2025-08-19Also stopped (terminated): Yale University, [18F]FPEB with PET (NCT05664763)
- 2025-08-14Phase 3 first posted: Wayne State University, Low-Dose Cannabidiol + Placebo Matched to Moderate-Dose Cannabidiol (NCT07123467)
- 2025-08-14Results posted on the registry: Medical University of South Carolina, Cannabidiol (NCT05317546)
- 2025-08-07Results posted on the registry: University of Florida, oral cannabinoid + oral codeine/acetaminophen (NCT05477875)
- 2025-08-06Results posted on the registry: University of Florida, Active CBD + Vehicle Control (Placebo) (NCT04586712)
- 2025-08-01Results posted on the registry: University of California, Los Angeles, Cannabidiol (CBD) 600 mg + Placebo (NCT03787628)
- 2025-07-31Results posted on the registry: Food and Drug Administration (FDA), Cannabidiol + Placebo (NCT06192589)
- 2025-07-29Results posted on the registry: Dana-Farber Cancer Institute, Cannabidiol (NCT04482244)
- 2025-07-25Results posted on the registry: Cardiol Therapeutics Inc., Cannabidiol, pharmaceutically produced with < 5 ppm THC + Placebo (NCT04615949)
- 2025-07-03Results posted on the registry: University of Virginia, CBD + Shea Butter (NCT04611347)
- 2025-06-11Results posted on the registry: The University of Texas Health Science Center, Houston, Standard of Care (acetaminophen +naproxen +gabapentin + as needed oxycodone or Tramadol) + Dronabinol (NCT05820685)
- 2025-06-11Also stopped (terminated): The University of Texas Health Science Center, Houston, Standard of Care (acetaminophen +naproxen +gabapentin + as needed oxycodone or Tramadol) + Dronabinol (NCT05820685)
- 2025-06-08Results posted on the registry: Wake Forest University Health Sciences, a drug against CNR1 (NCT06358144)
- 2025-05-22Results posted on the registry: Johns Hopkins University, Placebo + THC (NCT04130633)
- 2025-05-09Results posted on the registry: Johns Hopkins University, Dronabinol (Marinol®) + Placebo (NCT02792257)
- 2025-05-09Results posted on the registry: University of Michigan Rogel Cancer Center, Cannabidiol (CBD) (NCT04754399)
- 2025-05-02Phase 3 first posted: Vertanical GmbH, VER-01 (NCT06956014)
- 2025-04-24Also stopped (withdrawn): Dr. Paul Lyons, PO BRC-003 (High Cannabidiol Cannabis Extract) + Placebo (NCT06523725)
- 2025-04-23Phase 3 first posted: Icahn School of Medicine at Mount Sinai, Cannabidiol + Placebo (NCT06940674)
- 2025-04-10Results posted on the registry: Shanna Babalonis, PhD, Vaporized Marijuana + Opioid Agonist (NCT03705559)
- 2025-04-04Results posted on the registry: Milton S. Hershey Medical Center, Cannabidiol (CBD) Extract + Norethindrone Acetate (NCT04527003)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision